Modelling projections for the uptake of edoxaban in an European population to 2050: Effects on stroke, thromboembolism, and health economics perspectives

Europace

Volumn 18, Issue 10, 2016, Pages 1507-1513

  Blann, Andrew D ^a   Boriani, Giuseppe ^b   Lip, Gregory Y H ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

Atrial fibrillation; Edoxaban; Europe; Oral anti coagulation; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; EDOXABAN; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DRUG COST; DRUG UTILIZATION; EMBOLISM; EUROPEAN; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINUS RHYTHM; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; CLINICAL PRACTICE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST CONTROL; ECONOMIC MODEL; ECONOMICS; EUROPE; FORECASTING; ORAL DRUG ADMINISTRATION; STROKE; TIME FACTOR; TREATMENT OUTCOME; TRENDS;

ADMINISTRATION, ORAL; ATRIAL FIBRILLATION; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; EUROPE; FACTOR XA INHIBITORS; FORECASTING; HUMANS; MODELS, ECONOMIC; PRACTICE PATTERNS, PHYSICIANS'; PYRIDINES; STROKE; THIAZOLES; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84995579613     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euw211     Document Type: Article

References (29)

1. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014;6:213-20.
2. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53.
3. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 2013;167:1807-24.
4. Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013;34:2746-51.
5. Heeringa J. Atrial fibrillation: is the prevalence rising? Europace 2010;12:451-2.
6. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114:119-25.
7. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
8. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9.
9. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012;33:2719-47.
10. Heidbuchel H, Verhamme P, Alings M, Antz M, HackeW, Oldgren J et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51.
11. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2013;369:2093-104.
12. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012;107:584-9.
13. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW et al.; European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26:2422-34.
14. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014;16:308-19. Erratum in: Europace 2014;16:941.
15. Pisters R, Nieuwlaat R, Lane DA, Crijns HJ, Lip GY. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost 2013;109:328-36.
16. Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 2014;35: 3365-76.
17. Gerzeli S, Tarricone R, Zolo P, Colangelo I, Busca MR, Gandolfo C. The economic burden of stroke in Italy. The EcLIPSE Study: Economic Longitudinal Incidencebased Project for Stroke Evaluation. Neurol Sci 2005;26:72-80.
18. Kolominsky-Rabas PL, Heuschmann PU, Marschall D, Emmert M, Baltzer N, Neundö rfer B et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke 2006;37:1179-83.
19. Ali AN, Howe J, Abdel-Hafiz A. Cost of acute stroke care for patients with atrial fibrillation compared with those in sinus rhythm. Pharmacoeconomics 2015;33: 511-20.
20. Lloyd-Jones DM,Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110:1042-6.
21. Blann AD, Pisters R, Lip GYH. Net clinical benefit of edoxaban for stroke, mortality and bleed risk. Modelling for a European population. JACC Clin Electrophysiol 2016;2: 47-54.
22. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events-European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014;16:6-14.
23. Lip GY, Larsen TB, Skjøth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012;60:738-46.
24. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383:955-62.
25. Caldeira D, Barra M, Pinto FJ, Ferreira JJ, Costa J. Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol 2015; 262:516-22.
26. Cameron C, Coyle D, Richter T, Kelly S, Gauthier K, Steiner S et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open 2014; 4:e004301. doi:10.1136/bmjopen-2013-004301.
27. Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. J Med Econ 2015;18:399-409.
28. Yoneda Y, Okuda S, Hamada R, Toyota A, Gotoh J,WatanabeM et al. Hospital cost of ischemic stroke and intracerebral hemorrhage in Japanese stroke centers. Health Policy 2005;73:202-11.
29. Cotte FE, Chaize G, Kachaner I, Gaudin AF, Vainchtock A, Durand-Zaleski I. Incidence and cost of stroke and haemorrhage in patients diagnosed with atrial fibrillation in France. J Stroke Cerebrovasc Dis 2014;23:e73-83.